Health: Alzheimers Care
Roche and Eli Lilly’s blood test, cleared by the FDA the same year, also targets amyloid and tau markers. Both assays aim to streamline risk assessment and support therapeutic decision‑making across diverse care environments. The availability of these tests could reduce diagnostic delays, lower costs associated with late‑stage care, and facilitate timely enrollment in disease‑modifying trials. Early detection remains a priority as the Alzheimer’s disease prevalence rises, underscoring the importance of accessible, reliable screening tools in routine practice.
qz.com
Focused Ultrasound Foundation